Strengthening endemic country capacity to advance new treatments

Group of person discussing in front of a computer

Conducting clinical trials on neglected diseases means that research must often be conducted in some of the most remote areas of the world, where there is little infrastructure of any kind, let alone health infrastructure. In some areas, there can also be a risk of political instability. While carrying out clinical research at international standards of quality in such conditions is possible, it requires considerable effort to ensure adequate infrastructure, well trained staff, as well as specialized ethics committees, and well-functioning regulatory authorities are in place.

Maintaining and building R&D regional platforms

As an integral part of DNDi’s model, R&D regional research platforms form part of a broader, positive trend of research networks to maximize worldwide collaborations. The objective is to bring together key regional actors (ministries of health, national control programmes, regulatory authorities, academia, civil society groups, pharmaceutical companies, clinicians and health professionals) to share different experiences, knowledge, and problem-solving techniques.


Leishmaniasis East Africa Platform (LEAP) on leishmaniasis

HAT Platform on sleeping sickness, or human African trypanosomiasis

Chagas Clinical Research Platform (CCRP) on Chagas disease

redeLeish logo

redeLEISH Network on leishmaniasis

 

 

Building health infrastructure, creating R&D training spaces, and setting up research facilities in clinical trial sites

The physical upgrading of facilities needed for clinical research (such as patient wards and diagnostics laboratories) is undertaken by DNDi at trial sites to ensure they are compliant with Good Clinical Practice (GCP) international standards and remain the property of the local public health provider.

 

Graphic showing the number of people trained through the different platforms (Chagas, HAT, LEAP, Filarial)

Training to support R&D efforts in disease-endemic countries

Trained staff are needed to carry out GCP compliant trials. Training is important not just at the start of a trial, but is a continuous process which involves upgrading existing skill-sets and training new staff members. From external consultants to experienced trial site staff, the sharing of better practice principles helps to motivate teams working in difficult field conditions. In 2016, 628 people were trained across the LEAP, HAT and CCRP platforms.

 

 

Transferring technology to local manufacturers

For DNDi, the transfer of technology consists of transferring the industrial development know-how to partners in disease endemic regions to ensure a wide-spread distribution of treatments. It involves providing the required regulatory files and information needed to maintain competitive prices and reinforce the technological and scientific capacities of disease-endemic countries. More information